BLeeding Events and Maintenance DoSe of PraSugrel

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 195 participants.

Also called NCT01790854

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 195 participants (enrolled count) (from the registry)
Sponsor
David Antoniucci (from the registry)
Registry
  • NCT NCT01790854
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Italy (from the registry)
Registry status
  • Terminated (from the registry)

Technical summary

Registry record NCT01790854. Randomized; no masking; primary purpose treatment. Start 2012-11 (registry gives no type); primary completion 2014-10 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
BLeeding Events and Maintenance DoSe of PraSugrel
Acronym
BLESS
Condition
Adverse Reaction to Antiplatelet Agent
Condition
Acute Coronary Syndrome
Intervention (Drug)
Prasugrel dose 5 mg/day
Intervention (Drug)
Prasugrel dose 10 mg/day
Lead sponsor
David Antoniucci (class: other)
Collaborator
A.R. CARD Onlus Foundation (class: other)

Record details

Record id
cardio:ct-nct01790854
Content hash
372fafb219697d3b53898c79635eca136d05454fd6892c3683ea4309e611f6c4